Healthcare >> CEO Interviews >> July 19, 2004
STEPHEN M. SIMES has been Vice Chairman, President and CEO of BioSante
Pharmaceuticals, Inc., since January 1998. Prior to BioSante, Mr. Simes was
President and CEO of Unimed Pharmaceuticals, Inc., and Gynex Pharmaceuticals,
Inc., both of which were sold to bigger companies, Unimed to Solvay and Gynex to
Bio-Technology General Corp. (now Savient Pharmaceuticals, Inc.). Mr. Simes
started his career in the pharmaceutical industry with G.D. Searle & Co. in
1974. Since 1984, he has specialized in emerging companies, building product
portfolios in endocrinology, urology, hormones and drug delivery systems, among
other areas. Mr. Simes holds a BS in Chemistry from Brooklyn College of the City
University of New York and an MBA from New York University. Profile
TWST: Give us a brief overview of your company and BioSante's concept ofdrug development.
Mr. Simes: BioSante is developing our product pipeline in order to
increase stockholder value. Our